<DOC>
	<DOCNO>NCT00056160</DOCNO>
	<brief_summary>Randomized subject receive CC-5013 plus high-dose dexamethasone placebo appear identical CC-5013 plus high-dose dexamethasone 4-week cycle . Each subject participate treatment phase follow-up phase .</brief_summary>
	<brief_title>CC-5013 Plus Dexamethasone Versus Dexamethasone Alone Previously Treated Subjects With Multiple Myeloma</brief_title>
	<detailed_description>This phase 3 , multicenter , double-blind , placebo-controlled , parallel-group study efficacy safety CC-5013 plus oral pulse high-dose dexamethasone oral pulse high-dose dexamethasone therapy alone subject relapse refractory multiple myeloma . Eligible subject randomize 1:1 ratio 1 2 treatment group : Subjects CC-5013/Dex treatment group take 25 mg CC-5013 orally daily Days 1 21 match placebo capsule daily Days 22 28 28-day cycle ; Subjects Placebo/Dex treatment group take 1 placebo capsule Days 1 28 28-day cycle . Subjects treatment group take 40 mg dexamethasone orally daily Days 1 4 , 9 12 , 17 20 28-day cycle first 4 cycle therapy . Beginning Cycle 5 , dose dexamethasone reduce 40 mg orally daily Days 1 4 remain cycle .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Prior current diagnosis DurieSalmon stage II III multiple myeloma . No 3 previous antimyeloma regimens No highdose dexamethasone ( total monthly dose dexamethasone great 200 mg ) within 6 month study randomization . Measurable level myeloma paraprotein serum urine ( 24hour collection sample ) . Prior development disease progression highdose dexamethasone contain therapy . Laboratory abnormality : Absolute neutrophil count less 1,000 cells/mm cub Laboratory abnormality : Platelet count le 75,000/mm cubed Laboratory abnormality : Serum creatinine great 2.5 mg/dL Laboratory abnormality : Serum glutamic oxaloacetic transaminase ( SGOT , aspartate transaminase [ AST ] ) serum glutamic pyruvic transaminase ( SGPT , alanine transaminase [ ALT ] ) great 3.0 x upper limit normal Laboratory abnormality : Serum total bilirubin great 2.0 mg/dL Prior history malignancy multiple myeloma unless subject free disease great equal 5 year . Known hypersensitivity thalidomide dexamethasone . Development desquamate rash take thalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Refractory Relapsed</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC5013</keyword>
</DOC>